🎄🌟 🎉 Wishing our readers a Merry Christmas and a Happy New Year filled with new possibilities! 🎄🌟 🎉

Monday, 23 December 2024


STA Pharma, Regulus team up for mRNA targeting drugs

23 February 2018 | News

STA recently established oligonucleotide R&D labs at both its facilities in San Diego, California and Changzhou, China.

Image credit- cnbc.com

Image credit- cnbc.com

A WuXi AppTec group company, STA Pharmaceutical Co., the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing, and Regulus Therapeutics, a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing.

Under the agreement, STA will become a new strategic development and manufacturing partner for Regulus' preclinical and clinical programs of microRNA-targeting drugs used to treat a broad range of diseases. Regulus will provide STA with expertise, technical know-how, and training in the field of oligonucleotide scale-up.

STA recently established oligonucleotide R&D labs at both its facilities in San Diego, California and Changzhou, China. The state-of-the-art oligonucleotide GMP manufacturing facility at Changzhou will become operational later this year.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account